Biotechnology Following a positive European Medicines advisory panel recommendation at the end of January, RNAi therapeutics company Alnylam Pharmaceuticals yesterday announced that the European Commission (EC) has granted marketing authorization for Givlaari (givosiran), an injection for subcutaneous use targeting aminolevulinic acid synthase 1 (ALAS1) for the treatment of acute hepatic porphyria (AHP) in adults and adolescents aged 12 years and older. 4 March 2020